These Drugs Could Cut Health Costs by $250B

Disputes over the legitimacy of drug patents are just one of the roadblocks experts say prevent a new wave of innovative drugs from reaching their industry-changing potential.

The drugs, known as biosimilars, essentially replicate existing treatments. They are often compared with generics, which have upended drug pricing over the last three decades. But biosimilars, which could themselves save the U.S. health care system $250 billion over the next 10 years, might also widen access to treatments for complex diseases including cancer, multiple sclerosis and diabetes.